Showing 631-640 of 1781 results for "".
Women in Aesthetics: Alesheia Randolph Bush, MBA
https://reachmd.com/ma-issues-index/2025-mar-apr/women-in-aesthetics-alesheia-randolph-bush-mba/36072/Get to know Alesheia Randolph Bush, MBA, VP-Global Professional + Industry Relations for ZO Skin Health, Inc.Reducing Patient Time Burden in HER2+ Breast Cancer with Subcutaneous Trastuzumab/Pertuzumab
https://reachmd.com/programs/project-oncology/reducing-patient-time-burden-in-her2-breast-cancer-with-subcutaneous-trastuzumabpertuzumab/32996/A time and motion substudy within the ADEPT trial demonstrates that subcutaneous administration of trastuzumab and pertuzumab significantly reduces treatment time compared to intravenous delivery in patients with early-stage HER2-positive breast cancer. These time savings could help enhance patientUnderstanding Difficult-to-Treat Axial Spondyloarthritis in Real-World Practice
https://reachmd.com/programs/living-rheum/understanding-difficult-to-treat-axial-spondyloarthritis-in-real-world-practice/54369/Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
https://reachmd.com/programs/neurofrontiers/spinal-muscular-atrophy-reveals-hidden-kidney-impairment-risk/54641/Reimagining the Aesthetic Surgery Experience
https://reachmd.com/topics/practice-development/reimagining-the-aesthetic-surgery-experience/49013/How Greenwich Street Surgical came to lifeEarly Initiation of Acoramidis in ATTR-CM: Importance and Long-Term Impacts
https://reachmd.com/programs/heart-matters/early-initiation-of-acoramidis-in-attr-cm-importance-and-long-term-impacts/35757/Acoramidis, a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), was studied in an open-label extension of the ATTRibute-CM trial to determine whether its early and sustained use improves clinical outcomes. Discover acoramidis’ long-term impacts on all-cause mortality and/or first cardiovCAR T-Cell Therapy: New Frontiers in Diffuse Systemic Sclerosis Treatment
https://reachmd.com/programs/living-rheum/car-t-cell-therapy-new-frontiers-in-diffuse-systemic-sclerosis-treatment/30073/CD19-targeted CAR T-cell therapy may offer lasting benefits for diffuse systemic sclerosis. Here’s what you should know.Rising Popularity of MedSpas Brings Increased Scrutiny Nationwide
https://reachmd.com/topics/practice-development/rising-popularity-of-medspas-brings-increased-scrutiny-nationwide/54392/Legal, ownership, and scope-of-practice risks take center stage as the aesthetic market expandHonoring Age with Science and Strategy
https://reachmd.com/ma-issues-index/july-august-2025/honoring-age-science-strategy/36655/Mature beauty is not a consolation prize. It is an architectural project that honors decades of expression and experience. Diagnose every layer, match modality to mechanism, and remind your patient that elegance at 80 is never accidental. It is engineered.Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
https://reachmd.com/programs/project-oncology/early-liquid-biopsy-in-advanced-lung-cancer-real-world-data-suggest-targeted-gains/39033/